EDISON

RedHill Biopharma

Movantik acquisition completed; sales booked

RedHill is now promoting Aemcolo for travellers' diarrhoea (since December 2019), Talicia for H. pylori eradication (since March 2020) and the most recent addition, Movantik, for opioid-induced constipation (acquired from AstraZeneca on 1 April 2020). Movantik is an established product and AstraZeneca reported 2019 sales of \$96m in the US, so it is a significant addition to RedHill's portfolio. In April, the company booked \$7.3m Movantik sales, which seems a good result given this was the peak month of the COVID-19 pandemic. Promotion of the novel drugs, Talicia and Aemcolo, is affected by the ongoing pandemic and RedHill had to postpone certain promotional activities, but we believe the potential of these drugs is intact. Our valuation is \$593m or \$16.5 per ADS.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/18	8.4	(38.8)	(0.17)	0.0	N/A	N/A
12/19	6.3	(42.1)	(0.14)	0.0	N/A	N/A
12/20e	93.0	(9.7)	(0.03)	0.0	N/A	N/A
12/21e	137.0	3.2	0.01	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles and exceptional items.

First sales of Movantik booked

The company finalised its acquisition of Movantik from AstraZeneca on 1 April 2020, in line with planned timelines, which is an achievement in itself given the ongoing pandemic and worldwide restrictions limiting business activities. April, with sales of \$7.3m, was the first and full month that RedHill started to promote the new drug. AstraZeneca reported 2019 Movantik sales of \$96m. With the caveat that no reliable inferences can be made from one month's data, RedHill's sales seem to have held up well given that imposed restrictions in the US were at a peak in April.

COVID-19: Challenges and opportunities

In our <u>last report</u> we highlighted that the COVID-19 pandemic presented not only challenges, but also an opportunity as RedHill's two assets at earlier R&D stages have antiviral activity against corona viruses. In early April, RedHill made its Phase IIa stage asset opaganib (Yeliva) available for compassionate use in severe-to-critical COVID-19 patients. Following early insights from the compassionate use programme, RedHill filed for an IND with the FDA, which was approved in May. A randomized, double-blind, placebo-controlled Phase IIa study with severe-to-critical COVID-19 patients (n=40) is about to start.

Valuation: \$593m or \$16.5 per ADS

Our RedHill valuation is somewhat lower at \$593m or \$16.5 per ADS, versus \$638m or \$18.1 per ADS previously, which is mainly technical, as we now include the debt (\$78.2m at end Q120) used to acquire Movantik in our net cash calculation. As described above, a significant part of that amount has already been paid to AstraZeneca. In our previous report, we had already included Movantik's sales potential in our model, which led to an upgrade of our estimates. Our near-term estimate revisions have had only a small negative effect, which was largely counterbalanced by rolling the model forward.

Q120 company update

Pharma & biotech

	29 May 2020
Price	US\$7.0
Market cap	US\$251m
Net cash (\$m) at end Q120; \$52. payment to AstraZeneca for Mova was made on 1 April 2020	
Shares in issue	358.9m
Free float	90%
Code	RDHL
Primary exchange	Nasdaq

Share price performance



Business description

Speciality pharma company RedHill Biopharma focuses on gastrointestinal diseases and promotes several GI products in the US. The commercial portfolio includes Movantik (opioid-induced constipation), Talicia (H. pylori eradication) and Aemcolo (travellers' diarrhoea). The most advanced R&D assets are RHB-204 for NTM, RHB-104 for Crohn's disease, BEKINDA for gastroenteritis and IBS-D.

Next events

Initiation of pivotal Phase III st RHB-204 for NTM infections	udy with	Q320
Initiation of the Phase IIa stud opaganib for COVID-19 patier	,	Q2/Q320
Updates on the promotion of t commercial portfolio drugs	he	2020
Analyst		
Jonas Peciulis	+44 (0)20 30	77 5728

healthcare@edisongroup.com Edison profile page

RedHill Biopharma is a research client of Edison Investment Research Limited



Commercial portfolio update

Movantik: An established drug, latest addition to portfolio

We introduced the newest addition to RedHill's portfolio, Movantik, in our <u>previous report</u>. The company finalised the acquisition from AstraZeneca on 1 April 2020, in line with planned timelines, which is an achievement in itself given the ongoing pandemic and worldwide restrictions. With regard to further COVID-19 effects, RedHill highlighted in its Q120 presentation that the commercial team has continued to provide support to prescribers. As the lockdown restrictions are easing in certain areas, the salesforce is resuming more active promotion with in-person visits.

Movantik is the first oral PAMORA drug approved by the FDA and recommended in the guidelines from the American Gastroenterological Association (AGA) and the National Comprehensive Cancer Network (NCCN). Movantik was originally developed by Nektar Therapeutics, which out-licensed it to AstraZeneca in 2009. The drug was approved by the FDA in 2014 and launched in the US in 2015. AstraZeneca described Movantik as an 'important established medicine and the divestment to RedHill will ensure its continued availability for patients'.

Talicia and Aemcolo: Both novel GI drugs now launched

Aemcolo and Talicia were launched in December 2019 and March 2020, respectively. Express Scripts and Prime Therapeutics have already added Talicia to their formularies, while RedHill is working to increase coverage further. As Talicia was only launched at the end of the quarter, no financial data were reported with the Q120 results. In addition, promotion was affected by the ongoing COVID-19 pandemic. While it is still too early to estimate the full impact of the pandemic, RedHill indicated that certain activities related to the promotion of these drugs during the launch phase have been affected and postponed by approximately one quarter. In addition, the launch of Aemcolo, which is indicated for travellers' diarrhoea, was affected by widespread restrictions on international travel. Nevertheless, RedHill is confident that in a more normalised business and healthcare provision environment, its salesforce will resume promotion at full capacity. The company also highlighted strong interest in the novel drugs from healthcare professionals.

R&D update

Rapidly progressing COVID-19 programme

Opaganib is a sphingosine kinase-2 (SK2) inhibitor and has broad potential in oncology and inflammatory diseases, as well as anti-viral properties. In early April, RedHill made its Phase IIa stage asset opaganib (Yeliva) available for compassionate use in severe-to-critical COVID-19 patients. The company also reported findings from the first six patients who were hospitalised in Israel, hypoxic and required high-flow supplemental oxygenation. All six patients demonstrated improvement in clinical symptoms and biomarkers, including a reduced requirement for supplemental oxygenation, higher lymphocyte counts and decreased C-reactive protein levels. All patients were weaned from oxygen and at no stage during the treatment was mechanical ventilation needed. RedHill continues to work with all stakeholders involved to expand the compassionate use of opaganib in several countries. This will allow it to generate retrospective data and insight in a cost-effective way.

Following early insights from the compassionate use of opaganib, RedHill filed for an IND with the FDA, which was approved in May. This will be a randomized, double-blind, placebo-controlled Phase IIa study with the goal of enrolling up to 40 patients with severe-to-critical COVID-19 infection requiring hospitalisation and high-flow supplemental oxygenation. The study is about to start in US centres.



RedHill also has another asset, RHB-107 (upamostat). RHB-107 is an inhibitor of the S1 family of trypsin-like serine proteases with potential for use in the treatment of cancer, inflammatory lung diseases and irritable bowel syndrome. Based on its possible mechanism of action, RHB-107 was selected for in vitro testing by the US National Institute of Allergy and Infectious Diseases (NIAID).

Opaganib (Yeliva) for cholangiocarcinoma and prostate cancer


Enrolment in a Phase IIa trial with opaganib is complete, with a total of 39 cholangiocarcinoma patients. RedHill reported that preliminary data shows signs of activity and that these findings will be presented at a conference before the end of this year. While the data are still early, they could provide the first insights into clinical activity. The Medical University of South Carolina (MUSC) also initiated an investigator-sponsored (supported by the National Cancer Institute grant) study with opaganib in prostate cancer and patient enrolment is ongoing.

RedHill seems confident in this asset and is expanding the programme in cholangiocarcinoma. The company added a second arm to the study, in which opaganib will be combined with hydroxychloroquine. Enrolment will start when the COVID-19 pandemic improves. For clarity, the fact that opaganib will be combined with hydroxychloroquine is a coincidence. This drug (or derivatives) are currently attracting strong research interest as potential agents against COVID-19. RedHill mentioned it has been working on the potential of this combination for a while now. There will also be a third arm added, where opaganib will be combined with RedHill's other asset RHB-107 (upamostat).

RHB-204 for NTM infections

Supportive preclinical studies are complete, with positive results and RedHill plans to initiate a single, pivotal Phase III evaluating RHB-204 as a first-line, standalone treatment for pulmonary nontuberculous mycobacterium (NTM) infections caused by Mycobacterium avium complex (MAC) in Q320, subject to further input from the FDA.

Exhibit 1: RedHill's product portfolio and R&D pipelines



Source: RedHill



Financials

RedHill booked Q120 sales of \$1.1m, which came from its speciality GI products (Donnatal, EnteraGam and Mytesi). Going forward, these products will no longer be the driver, as RedHill decided to discontinue the promotion of these products and from now on will focus on its GI drugs Talicia, Aemcolo and Movantik. We had previously adjusted our revenue estimates to take account of this.

RedHill reported sales of Movantik of \$7.3m in April alone, the first full month of promotion after it was acquired from AstraZeneca. We had already included Movantik sales in our model in <u>our last</u> report, which is an established product, and make no changes to our forecasts. With regards to Talicia and Aemcolo, as described above, the COVID-19 pandemic presents significant challenges for promotion of the novel products. We therefore reduced our near-term sales estimates for these drugs somewhat to reflect the delay of full promotion activities by one quarter, but see the peak potential as intact. Our updated total sales for 2020 and 2021 are \$93.0m (vs \$99.0m previously) and \$137.0m (vs \$141.0m previously), respectively.

Q120 operating expenses were \$16.4m vs \$7.9m in Q119, reflecting a y-o-y increase due to a higher level of commercial activities. In Q120, S&M costs were \$9.0m (vs \$3.1m in Q119), G&A costs were \$4.6m (vs \$2.0m), while R&D expenses decreased to \$2.8m vs \$5.4m in Q119. We had already assumed an increase in costs associated with the US organisation and commercialisation of the GI drugs. This is somewhat counterbalanced by lower R&D spending. In addition, the delay in certain promotional activities should lead to lower than expected spending during pandemic restrictions. After fine-tuning our spending forecasts, our near-term EBIT estimates are a loss of \$9.7m in 2020 (vs \$14.0m previously), but a profit of \$3.2m in 2021 (vs \$9.6m previously).

Reported cash and cash equivalents were \$115.1m at the end of Q120. In conjunction with the acquisition of Movantik, RedHill entered into a royalty-backed term loan totalling \$115m from HealthCare Royalty Partners (HCR). During Q120, RedHill received a total of \$80m and made an upfront payment of \$52.5m to AstraZeneca on 1 April 2020. The cash balance following completion of the transaction was \$62.5m. RedHill could still receive, if needed, a total of \$35m from HCR depending on certain commercial conditions. In addition, in May 2020 RedHill carried out a small private placement of 618k of ADSs (compared to 35.3m ADSs outstanding) raising \$4.7m.

This available non-dilutive funding allowed RedHill to ramp up its salesforce, which it needs to optimise promotion of the three products. Both Talicia and Aemcolo were launched recently, so by the end of FY20 initial performance will provide insights into the commercial potential of these products and should also serve as a catalyst for the share price.

Valuation

Our RedHill valuation is somewhat lower at \$593m or \$16.5 per ADS, versus \$638m or \$18.1 per ADS previously. The decrease is mainly a technical adjustment, in that we now include end Q120 debt of \$78.2m in our net cash calculation. As described above, a significant part of that amount has already been paid to AstraZeneca. In our <u>previous report</u> we had already included Movantik's sales potential in our model, which led to an upgrade of our estimates. The near-term (mainly COVID-19 related) estimate revisions have only a small negative effect, which was largely counterbalanced by rolling the model forward. As previously, we include RedHill's most advanced R&D assets with unchanged assumptions.



Exhibit 2: RedHill sum-of-the-parts valuation

Product	Launch	Peak sales (\$m)	NPV (\$m)	NPV/share (\$)	Probability	rNPV (\$m)	rNPV/share (\$)
GI specialty products (including Talicia, Aemcolo and Movantik)	Marketed		415.3	11.6	100%	415.3	11.57
RHB-104 - Crohn's disease	2023	145	96.1	2.7	50%	48.1	1.34
RHB -204 - NTM infections	2024	50	61.8	1.7	30%	17.3	0.48
Bekinda - Gastroenteritis	2022	21	39.2	1.1	85%	33.1	0.92
- IBS-D	2023	201	119.6	3.3	60%	78.4	2.18
Yeliva - Cholangiocarcinoma	2024	115	206.8	5.8	10%	16.9	0.47
Net cash/(debt) (end-Q120 adj.)*			(15.7)		100%	(15.7)	(0.44)
Valuation			923.2	26.16		593.4	16.54

Source: Edison Investment Research. Note: WACC = 12.5% for product valuations. IBS-D = irritable bowel syndrome; NTM = nontuberculous mycobacteria. *Includes 1 April 2020 Movantik acquisition.



Exhibit 3: Financial summary

	\$'000s 2018	2019	2020e	20216
Year end 31 December	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS				
Revenue	8,360	6,291	93,006	136,969
Cost of Sales	(2,837)	(2,259)	(33,652)	(49,013
Gross Profit	5,523	4,032	59,354	87,956
Research and development	(24,862)	(17,419)	(11,200)	(11,200
EBITDA	(39,241)	(41,988)	(9,513)	3,377
Operating Profit (before amort. and except.)	(39,331)	(42,985)	(9,651)	3,208
Intangible Amortisation	0	(216)	0	(
Exceptionals	0	0	0	(
Other	0	0	0	(
Operating Profit	(39,331)	(43,201)	(9,651)	3,208
Net Interest	511	897	0	(
Profit Before Tax (norm)	(38,820)	(42,088)	(9,651)	3,208
Profit Before Tax (reported)	(38,820)	(42,304)	(9,651)	3,208
Tax	0	0	0	(802
Profit After Tax (norm)	(38,820)	(42,088)	(9,651)	2,406
Profit After Tax (reported)	(38,820)	(42,304)	(9,651)	2,406
Average Number of Shares Outstanding (m)	231.2	296.9	355.9	359.
EPS - normalised (\$)	(0.17)	(0.14)	(0.03)	0.0
EPS - normalised fully diluted (c)	(16.79)	(14.17)	(0.03)	0.0
EPS - (reported) (\$)	(0.17)	(0.14)	(0.03)	0.0
Dividend per share (\$)	0.0	0.0	0.0	0.0
Gross Margin (%)	66.1	64.1	63.8	64.2
EBITDA Margin (%)	N/A	N/A	N/A	2.
Operating Margin (before GW and except.) (%)	N/A	N/A	N/A	2.3
BALANCE SHEET				
Fixed Assets	5,623	20,885	73,450	88,484
Intangible Assets	5,320	16,927	69,462	84,497
Tangible Assets	163	228	258	257
Investments	140	3,730	3,730	3,730
Current Assets	56,788	53,214	78,725	69,124
Stocks	769	1,882	1,882	1,882
Debtors	2.834	3,460	3,460	3,460
Cash	29.005	29,023	54,534	44,93
Other*	24,180	18,849	18,849	18,849
Current Liabilities	(10,381)	(10,616)	(10,616)	(10,616
Creditors	(10,381)	(10,616)	(10,616)	(10,616
Short term borrowings	(10,001)	0	(10,010)	(10,010
Long Term Liabilities	(844)	(3,481)	(82,981)	(82,981
Long term borrowings	(044)	(3,401)	(80,000)	(80,000
Other long-term liabilities	(844)	(3,481)	(2,981)	(2,981
Net Assets	× /			()
	51,186	60,002	58,577	64,01
CASH FLOW				
Operating Cash Flow	(34,462)	(40,749)	(6,486)	6,404
Net Interest	0	0	0	(
Fax	0	0	0	(802
Capex	(23)	(168)	(168)	(168
Acquisitions/disposals	0	0	0	(
Financing	42,263	36,305	4,700	(
Other**	4,772	4,630	(52,535)	(15,035
Dividends	0	0	0	
Net Cash Flow	12,550	18	(54,489)	(9,601
Opening net debt/(cash)	(16,455)	(29,005)	(29,023)	25,466
HP finance leases initiated	0	0	0	(
Other	0	0	0	(
Closing net debt/(cash)***	(29,005)	(29,023)	25,466	35,067

Source: RedHill Biopharma accounts, Edison Investment Research. Note: *Bank deposits and financial assets at fair value. **Mainly Movantik acquisition payments to AstraZeneca. ***Net cash does not include bank deposits and financial assets.



General disclaimer and copyright

This report has been commissioned by RedHill Biopharma and prepared and issued by Edison, in consideration of a fee payable by RedHill Biopharma. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report represent those of any term of the determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2020 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment docision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom

New York +1 646 653 7026 1,185 Avenue of the Americas 3rd Floor, New York, NY 10036 United States of America Sydney +61 (0)2 8249 8342 Level 4, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia